Phase 1 study of ONO-7056

A Phase 1 study of ONO-7056 in patients with solid tumor

Status

Unknown

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080221709

Enrollment

Registered

2012-02-13

Start date

2012-02-13

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Solid tumor

Interventions

investigational material(s) Generic name etc : ONO-7056 INN of investigational material : Salirasib Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investigational

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1.20 years or older of age 2.Patients with solid tumor pathologically documented by tissue diagnosis or cytodiagnosis 3.Advanced/relapsed cancer patients with no standard or adequate therapeutic options

Exclusion criteria

Exclusion criteria: 1.Patients with active infection

Design outcomes

Primary

Measure	Time frame
Safety Pharmacokinetics, Efficacy, Biomarkers	—

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026